B6-hPD-1/hPD-L1 Mouse
製品名
B6-hPD-1/hPD-L1 Mouse
製品ID
I001202
系統名
C57BL/6Cya-Pdcd1em1(hPDCD1)Cd274em1(hCD274)/Cya
背景情報
C57BL/6Cya
状況
このマウス系統を論文で使用する場合は、「B6-hPD-1/hPD-L1 Mouse（カタログ番号I001202）はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
遺伝子別名
B7-H, B7H1, PDL1, PD-L1, hPD-L1, PDCD1L1, PDCD1LG1, PD1, PD-1, CD279, SLEB2, hPD-1, hPD-l, hSLE1
染色体
Chr 9, Chr 2
MGI ID
さらに
系統詳細
Programmed cell death protein 1 (PDCD1/PD-1) is a member of the B7-CD28 costimulatory receptor family. It is an inhibitory receptor expressed on activated T cells and plays a role in regulating the function of effector T cells, including CD8+ T cells, and promoting the differentiation of CD4+ T cells into regulatory T cells. PD-1 is expressed in a variety of tumors and plays an important role in antitumor immunity. In addition, PD-1 is involved in the defense against autoimmune diseases and has inhibitory effects on antitumor and antimicrobial immunity [1].
Programmed cell death 1 ligand 1 (PD-L1), also known as cluster of differentiation 274 (CD274) or B7 homolog 1 (B7H1), is an immune inhibitory receptor ligand. PD-L1 is a type I transmembrane protein with immunoglobulin V-like (IgV) and C-like (IgC) structural domains and is expressed by hematopoietic and non-hematopoietic cells, including T cells, B cells, and various types of tumor cells [2]. PD-L1 can bind to the PD-1 on the surface of CD8+ T cells, inhibiting the activity of CD8+ T cells. This interaction can prevent the immune system from damaging normal tissues, but it can also be used by tumor cells to escape immune surveillance. Monoclonal antibodies that competitively bind to PD-L1 can relieve the immune function inhibition mediated by the binding of PD-1 and PD-L1. This can reactivate CD8+ T cells, triggering the human body's anti-tumor immune response [3]. Therefore, developing of antibody drugs targeting PD-1 and PD-L1 is a hot area in tumor immunotherapy [3-5].
B6-hPD-1/hPDL1 mice are PD-1 and CD274 double humanized mouse models obtained by mating PD-1 humanized mouse models with CD274 humanized mouse models. They express human PD-1 and CD274 genomic sequences under the control of mouse promoters. This model is a valuable tool for studying cancer immunotherapy. In addition, this model also provides a powerful preclinical research platform for evaluating the efficacy and mechanism of therapeutic drugs targeting PD-1 and PD-L1.
参考文献
National Center for Biotechnology Information. (2024, February 1). PDCD4 programmed cell death 4 [Homo sapiens (human)] - Gene - NCBI. National Center for Biotechnology Information. https://www.ncbi.nlm.nih.gov/gene/5133
Kornepati AVR, Vadlamudi RK, Curiel TJ. Programmed death ligand 1 signals in cancer cells. Nat Rev Cancer. 2022 Mar;22(3):174-189.
Escors D, Gato-Cañas M, Zuazo M, Arasanz H, García-Granda MJ, Vera R, Kochan G. The intracellular signalosome of PD-L1 in cancer cells. Signal Transduct Target Ther. 2018 Sep 28;3:26.
Huang CY, Wang Y, Luo GY, Han F, Li YQ, Zhou ZG, Xu GL. Relationship Between PD-L1 Expression and CD8+ T-cell Immune Responses in Hepatocellular Carcinoma. J Immunother. 2017 Nov/Dec;40(9):323-333.
Zhang C, Wu S, Xue X, Li M, Qin X, Li W, Han W, Zhang Y. Anti-tumor immunotherapy by blockade of the PD-1/PD-L1 pathway with recombinant human PD-1-IgV. Cytotherapy. 2008;10(7):711-9.
系統作製戦略
① Gene editing strategy of B6-hPD-1 mice: The mouse Pdcd1 gene was edited using gene editing technology to replace the sequence encoding the extracellular domain of mouse PD-1 protein with the sequence from the human PD1 gene encoding the human PD-1 protein extracellular domain while retaining the mouse signal peptide.
② Gene editing strategy of B6-hPDL1-V(2) mice: The gene sequence encoding the extracellular domain (immunoglobulin V-like, IgV-like) of mouse PD-L1 protein was replaced with the corresponding human PD-L1 gene sequence, while the sequence encoding the signal peptide was retained.
Figure 1. Gene editing strategy of B6-hPD-1 mice.
Figure 2. Gene editing strategy of B6-hPDL1-V(2) mice.
適用分野
PD-1/PD-L1-targeted drug screening, development, and evaluation;
Research on the pathological mechanisms and therapeutic approaches of cancer immunotherapy.
お問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。